InvestorsObserver
×
News Home

What is the Market's View on AbbVie Inc (ABBV) Stock's Price and Volume Trends Friday?

Friday, June 09, 2023 03:41 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on AbbVie Inc (ABBV) Stock's Price and Volume Trends Friday?

AbbVie Inc (ABBV) stock is higher by 0.81% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
AbbVie Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ABBV!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ABBV Stock Today?

AbbVie Inc (ABBV) stock is trading at $137.98 as of 3:38 PM on Friday, Jun 9, an increase of $0.34, or 0.25% from the previous closing price of $137.64. Volume today is low. So far 2,709,641 shares have traded compared to average volume of 6,054,047 shares. The stock has traded between $137.08 and $139.19 so far today.

More About AbbVie Inc

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira, administered via injection. Click Here to get the full Stock Report for AbbVie Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App